
Looking to capitalize on genetic modifiers, Maze Therapeutics launches with $191M in financing led by Arch, Third Rock
Some people with disease-causing genetic mutations seem to escape illness, while members of a family with the same genetic aberration present with different forms and/or severity of a disease — for example cystic fibrosis. These inconsistencies suggest that the effects of a single genetic variant can be modified by other genes in our DNA, and monogenic diseases give scientists the opportunity to identify these genetic modifiers and harness them for therapeutic intervention. A company working on translating these insights into drugs — Maze Therapeutics — burst on to the scene on Thursday, with a $191 million infusion led by storied investors Third Rock Ventures and ARCH Venture Partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.